Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GENEVAX-HIV
- Development stage
- Phase 1
- Lead developer
- Pfizer
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular, Intradermal
01
Overview
GENEVAX-HIV (APL-400-003) is a candidate DNA vaccine developed for the prevention of HIV infection. It is designed to induce an immune response against HIV in seronegative individuals and has been evaluated in pilot studies using intramuscular or intradermal administration. The vaccine utilizes DNA technology to stimulate the body's immune system to recognize and respond to HIV antigens, aiming to provide protective immunity against the virus. It is being developed by Pfizer.
- Other names
- GENEVAX-HIV
02
Targets
HIV-1 antigens
Beyond the preview
Go deeper on GENEVAX-HIV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GENEVAX-HIV.